<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446715</url>
  </required_header>
  <id_info>
    <org_study_id>17062020</org_study_id>
    <nct_id>NCT04446715</nct_id>
  </id_info>
  <brief_title>Comparison of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Cesarean Section</brief_title>
  <official_title>Comparison of Clinical Effects of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Patients Undergoing Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makassed General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makassed General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subarachnoid block is a widely used anesthetic technique for cesarean section. To improve the
      quality of analgesia and prolong its duration, the addition of intrathecal opioids to local
      anesthetics has been encouraged.

      In a double blind randomized controlled trial, 60 parturient women ASA 2-3 scheduled for
      elective cesarean delivery under spinal anesthesia will be randomly divided into 2 groups:
      Group 1 will receive sufentanil 5 μg and Group 2 will receive meperidine 12.5 mg. In every
      group, 0.5% heavy bupivacaine 10 will be added.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A questionnaire will be used to collect data. Patients' demographic and operative
      characteristics will be recorded. These include block level, heart rate, mean arterial
      pressure, nausea, vomiting, shivering and use of vasopressors. Post-operative data include
      pain, analgesic consumption, nausea and vomiting, as well as patients and surgeons
      satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early postoperative analgesia</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>The duration of effective analgesia is defined as the time from intrathecal injection to first patient analgesic demand</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirements</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>A questionnaire will be used to record the analgesics consumed by the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Sufentanil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meperidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>Patients will receive sufentanil in spinal anesthesia</description>
    <arm_group_label>Sufentanil Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meperidine</intervention_name>
    <description>Patients will receive meperidine in spinal anesthesia</description>
    <arm_group_label>Meperidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Patients will receive 0.5% heavy bupivacaine in spinal anesthesia</description>
    <arm_group_label>Meperidine Group</arm_group_label>
    <arm_group_label>Sufentanil Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women with American Society of Anesthesiologist (ASA) 2-3

          -  scheduled for elective cesarean section.

        Exclusion Criteria:

          -  refuse to participate in the study

          -  ASA IV or V,

          -  requiring emergency obstetric care,

          -  with a history of hypersensitivity or allergy to any of the study drugs,

          -  those with any contraindication to the technique proposed,

          -  operation time longer than 1.5 hour,

          -  blood loss more than 1500 millilitres

          -  Body Mass Index (BMI)&gt;30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saleh Kanawati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makassed General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saleh Kanawati, MD</last_name>
    <phone>+9611636000</phone>
    <phone_ext>6405</phone_ext>
    <email>s.kanawati@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makassed General Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <contact>
      <last_name>Saleh Kanawati, MD</last_name>
      <phone>+9611636000</phone>
      <phone_ext>6405</phone_ext>
      <email>s.kanawati@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makassed General Hospital</investigator_affiliation>
    <investigator_full_name>Saleh Kanawati</investigator_full_name>
    <investigator_title>Acting chairperson</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

